Form 4: Belite Bio Director Reports Stock Transaction
Insider Transaction (Form 4)
Wan-Shan Chen, a Director of Belite Bio, Inc, reported multiple transactions in common stock on September 24, 2026.
Summary
- In-the-money derivative exercise: acquired 13,796 Ordinary Share at $0.44 ($6,051) on September 24, 2026; holds 37,259 after (Direct).
- In-the-money derivative exercise: disposed of 13,796 Stock Option (right to buy) on September 24, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Wan-Shan Chen — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-24 | In-the-money derivative exercise | Ordinary Share | 13,796 | $0 | $6.1K | 37,259 |
| 2026-09-24 | In-the-money derivative exercise | Stock Option (right to buy) | 13,796 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-24 | In-the-money derivative exercise (13,796 shares) |
| 2026-09-24 | In-the-money derivative exercise (13,796 shares) |
Keywords
insider transaction, Form 4, BLTE, BELITE BIO, INC, neutral, Wan-Shan Chen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.